MicroPort EP Obtains FDA Approval for EasyFinder™ Fixed Curve Diagnostic Catheter

Shanghai, China, 2 February 2023 – Recently, MicroPort EP obtained approval from the Food and Drug Administration in the United States of America (U.S.) for its independently researched and developed EasyFinder™ Fixed Curve Diagnostic Catheter. This product is the first mapping catheter from MicroPort EP to get FDA approval.

The EasyFinder™ Fixed Curve Diagnostic Catheter design comprises a catheter body and a connecting cable that can be used in combination with a multichannel electrophysiology (EP) recording system for the electrophysiological study of the heart.

The EasyFinder™ Fixed Curve Diagnostic Catheter has been certified by the FDA and entered into the U.S. market for sale, further promoting the internationalization process of the company's products, bringing positive impact on their promotion in global markets, and enhancing brand awareness, globally.

In the future, MicroPort EP will continue to invest in technological research and development, as well as product innovation, so as to provide more high-quality products and professional services, offering comprehensive EP diagnostic and therapeutic solutions for doctors and patients worldwide.

About MicroPort EP

Founded in Shanghai in 2010, Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort EP”, stock code: 688351.SH), a joint-stock subsidiary of MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK), is a global medical devices company focusing on the development, manufacturing, and marketing of minimally invasive medical devices for the treatment of cardiac arrhythmia disease. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. These products are used by hundreds of physicians at over 600 hospitals across China and beyond. At MicroPort EP, we strive to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.

More information is available at www.everpace.com